Latest Headlines

  1. Landmark Bio And Syngoi Technologies To Operate As Artis BioSolutions, An End-To-End Gene-To-GMP Platform For Genetic Medicines 7/29/2026

    Artis BioSolutions, an advanced therapies company built to streamline the discovery, development, and production of genetic medicines, today announced that both Landmark Bio, its Watertown, Massachusetts-based development and GMP manufacturing operation, and Syngoi, its Bilbao, Spain-based enzymatic synthetic DNA business, will now operate under the Artis BioSolutions name. 

  2. Kyverna Therapeutics And ElevateBio Enter Into Commercial Manufacturing And Supply Agreement For Miv-cel 7/27/2026

    Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical company developing cell therapies for patients with autoimmune diseases, and ElevateBio, a technology-driven advanced therapy contract development and manufacturing organization (CDMO), today announced a manufacturing agreement for both U.S. commercial and global clinical supply of miv-cel (mivocabtagene autoleucel), Kyverna’s autologous CD19 directed CAR T-cell therapy.

  3. FUJIFILM Biosciences And NextCell Launch New Commercial Platform Comprised Of RUO Stromal Cells And Cell Culture Media 7/27/2026
  4. Esco Lifesciences To Showcase Innovative Laboratory And Pharmaceutical Solutions At ISPE Singapore Conference & Exhibition 2026 7/17/2026

    Esco Lifesciences is pleased to announce its participation in the ISPE Singapore Conference & Exhibition 2026, taking place on 20–21 August 2026 at Suntec Singapore. Visitors are invited to meet the team at Booth 811 to explore the latest technologies supporting pharmaceutical manufacturing, aseptic processing, and laboratory operations.

  5. RoosterBio And Applied StemCell Partner To Advance Scalable iPSC-Based Bioprocess Solutions 7/8/2026

    Applied StemCell, Inc. ("ASC"), a biotechnology company with deep expertise and intellectual property in induced pluripotent stem cell (iPSC) technology, and RoosterBio, Inc., a leading supplier of cellular starting materials, bioprocess media, and advanced therapy manufacturing solutions, today announced a strategic partnership to develop and commercialize scalable iPSC-based bioprocess solutions.

  6. RoosterBio And Qkine Partner To Deliver A Single-Source Platform Of Cells, Media, And Growth Factors To U.S. Customers 7/7/2026

    RoosterBio, Inc., a leading supplier of cellular starting materials, bioprocess media, and advanced therapy manufacturing solutions for hMSCs, iPSCs, and exosome therapeutic developers, today announced a distribution agreement with Qkine Ltd., a Cambridge, UK–based manufacturer of high-purity, animal origin-free recombinant growth factors, cytokines, and complex bioactive proteins.

  7. CCRM At 15: Powering Canada's Rise In Cell And Gene Therapy 7/1/2026

    CCRM is proud to celebrate its 15th anniversary, marking a decade and a half of advancing regenerative medicine and helping to establish Canada as a global player in the maturing cell and gene therapy field.

  8. Rinn Advanced Therapies And CCRM Explore Establishment Of CCRM Ireland 6/29/2026

    Rinn Advanced Therapies, Ireland’s national research centre for personalized immune cell therapies, today announced the signing of a Memorandum of Understanding (MOU) with CCRM, a global leader in cell and gene therapy development and commercialization. The agreement outlines a strategic collaboration to explore establishing a CCRM-affiliated advanced therapies hub in Ireland.

  9. Proliant Health & Biologicals Raises The Albumin Standard With AlbufreeDX: Consistent, Animal-Free Recombinant Human Albumin 6/24/2026

    Proliant Health & Biologicals announces the commercial launch of AlbufreeDX, a recombinant human albumin (rHA) designed to meet the growing demand for high-performance, animal-free ingredients across diagnostic and life science applications.

  10. Asimov Launches Chrysalis Transposase, A Wholly-Owned Genome Integration Tool For Biotherapeutics Production 6/23/2026

    Asimov announces Chrysalis transposase, a proprietary genome integration tool engineered to deliver higher titers, greater expression stability, and faster cell recovery than conventional transposases.